Medtronic PLC (NYSE:MDT) Short Interest Update

Medtronic PLC (NYSE:MDT) saw a significant decrease in short interest in December. As of December 15th, there was short interest totaling 15,131,648 shares, a decrease of 20.3% from the November 30th total of 18,974,699 shares. Based on an average trading volume of 6,098,112 shares, the short-interest ratio is presently 2.5 days. Approximately 1.2% of the company’s shares are short sold. Approximately 1.2% of the company’s shares are short sold. Based on an average trading volume of 6,098,112 shares, the short-interest ratio is presently 2.5 days.

Institutional Trading of Medtronic

A number of hedge funds have recently bought and sold shares of the stock. Corundum Trust Company INC acquired a new stake in Medtronic in the 3rd quarter valued at $27,000. 1248 Management LLC bought a new stake in Medtronic during the 1st quarter worth about $26,000. Valley Wealth Managers Inc. acquired a new position in Medtronic in the third quarter valued at approximately $29,000. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the 2nd quarter worth $27,000. Finally, Imprint Wealth LLC acquired a new position in shares of Medtronic during the 3rd quarter worth about $31,000. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

Shares of NYSE MDT traded down $0.53 during trading on Thursday, hitting $96.13. The company had a trading volume of 4,718,874 shares, compared to its average volume of 5,493,663. Medtronic has a 52 week low of $79.38 and a 52 week high of $106.33. The company has a market cap of $123.24 billion, a P/E ratio of 25.91, a PEG ratio of 2.55 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The business’s 50-day moving average is $97.57 and its 200 day moving average is $93.94.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Barclays increased their price target on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Morgan Stanley boosted their price target on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Wells Fargo & Company raised their target price on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).